TOKYO -- Fujifilm Holdings has joined hands with German drugmaker Bayer to develop an immune-based cancer treatment using induced pluripotent stem cells.
Currently, stem cell treatments are expensive and take time to prescribe. The Japan-German alliance intends to surmount these hurdles by using a new method in which iPS cells come from someone other than the patient. In the conventional method, cells from patients themselves are used.
By continuing to browse this website, you accept cookies which are used for several reasons such as personalizing content/ads and analyzing how this website is used. Please review our
to learn how you can update your cookie settings.